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ABSTRACT 
Context: Metformin is frequently prescribed for 
the treatment of type 2 diabetes mellitus. It is 
recommended as a first line agent by the Ame- 
rican Diabetes Association. Vitamin B12 defi- 
ciency has been suggested as a side effect of 
metformin therapy; however, previous studies 
have not assessed the utility of methylmalonic 
acid levels as an indicator of vitamin B12 status. 
Objective: To investigate the prevalence of vita- 
min B12 deficiency in patients on metformin 
therapy for diabetes by utilizing both vitamin 
B12 and methylmalonic acid levels. Design, Set- 
ting, and Patients: Eighty-eight patients with dia- 
betes, who were either on or off metformin the- 
rapy for at least thirty days, were enrolled in a 
case-controlled study. Blood work and ques- 
tionnaires were used for analysis. Main Out- 
come Measures Study: Aims were to detect a 
clinically significant difference in the prevalence 
of vitamin B12 deficiency between metformin 
users and non-users, where such deficiency is 
defined by both low vitamin B12 and elevated 
methylmalonic acid levels. Results: Two Sample 
Equal Variance T-Tests were used to compare 
averages of measured values and the Chi- 
square test was used to determine the signifi- 
cance of calculated vitamin B12 deficiency rates 
between the two groups of patients. Two sepa- 
rate methods for defining vitamin B12 deficiency 
were utilized. There was no difference in the 
prevalence of vitamin B12 deficiency in metfor- 
min users compared with non-users by either 
method. Average homocysteine levels were 
higher in those not on metformin therapy. Con- 
clusion: Vitamin B12 deficiency as defined by an 
elevated methylmalonic acid level was no grea- 
ter in patients with diabetes on metformin ther- 
apy versus those patients not on metformin 
treatment. 
Keywords: Metformin; Vitamin B12; Methylmalonic 
Acid; Diabetes Mellitus 
1. INTRODUCTION 
There are 23.6 million people in the United States with 
diabetes mellitus (approximately 8% of the total popula- 
tion), and 90% - 95% of those have Type 2 diabetes. Cur- 
rently, the yearly cost burden of diabetes is estimated to 
be roughly $174 billion, and if current trends continue, 
one-third of the population will eventually develop dia- 
betes. In 2006, diabetes was the sixth leading cause of 
death in America [1]. 
One of the standard treatments for type II diabetes is 
metformin. Clinical trials such as the United Kingdom 
Prospective Diabetes Study have shown the long-term 
benefits of metformin in decreasing diabetic-associated 
complications, and metformin has become the most pre-
scribed oral hypoglycemic agent in the United States. 
However, metformin is not without adverse reactions. 
While gastrointestinal side effects are well-known, the 
link between metformin use and vitamin B12 deficiency 
is not as well recognized. Previous studies have sug-
gested a prevalence of vitamin B12 deficiency of up to 
30% in patients taking metformin [2,3]. Adams, et al. 
showed vitamin B12 levels returned to normal in half the 
patients who stopped taking the medication [3]. Met-
formin may affect vitamin B12 absorption by altering the 
secretion of intrinsic factor [4]. Dosage and chronicity of 
use of metformin have been studied as possible factors 
impacting vitamin B12 status [3].  
Elevated serum levels of homocysteine and methyl-
malonic acid have been shown to be more sensitive 
markers of vitamin B12 deficiency than serum B12 con-
centrations alone. However, unlike hyperhomocysteine-
mia, elevated methylmalonic acid is also highly specific 
for vitamin B12 deficiency. Some studies have shown 
slight elevations of homocysteine levels among patients 
taking metformin [4,5]. However, the correlation be-
tween metformin use and methylmalonic acid concentra-
tions has not been well studied.  
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2. MATERIALS AND METHODS 
2.1. Subjects 
Patients aged 20 - 80 years with a history of type 2 
diabetes who presented to Staten Island University Hos-
pital or its’ primary care clinic were screened for inclu-
sion in the study. Each patient was questioned about his 
or her diabetes history and medication use. Patients had 
to have been on or off metformin treatment for a mini-
mum of 30 days to be considered for the study. Patients 
were excluded if they were already on vitamin B12 re-
placement therapy or had a known history of vitamin 
B12 or folate deficiency. Other exclusion criteria in-
cluded a history of hematological cancer, methotrexate 
use, pernicous anemia, alcohol intake, adherence to a 
vegetarian diet, gastric surgery, and/or inflammatory 
bowel disease. Patients on insulin therapy were excluded 
as well. 88 patients met criteria and consented to partici-
pate in the study—47 were taking metformin alone or in 
combination with another oral hypoglycemic agent, and 
41 were on other oral hypoglycemic agents and had not 
taken metformin in the last 30 days. Each patient’s chart 
was reviewed to determine the dosage of metformin pre-
scribed.  
The study was approved by the hospital’s IRB com-
mittee and all patients provided written informed con-
sent. 
2.2. Laboratory Investigations 
Patients had their blood drawn at the time of an office 
visit in the primary care clinic or within 24 hours of 
presentation to the hospital (to avoid alteration of labo-
ratory data in response to hospital diabetes management). 
Vitamin B12, homocysteine, methylmalonic acid (MMA), 
serum creatinine, complete blood count (CBC), and gly-
cosylated hemoglobin (HgA1C) levels were obtained. 
Vitamin B12, MMA, and homocysteine levels were ana-
lyzed using immunoassay on the DXI by Beckman, a 
GC-MS analyzer, and a Chemiluminescent Immunoassay 
System on the Immulite by Johnson and Johnson respec-
tively. Standardized data collection forms were used to 
record the data for analysis.  
3. STATISTICAL METHODS 
This was a case-control study to determine the preva-
lence of Vitamin B12 deficiency in patients on metfor- 
min therapy for Type II Diabetes.  
The following criteria were used to assess Vitamin 
B12 deficiency: 
1) Vitamin B12 < 180 or 180 < Vitamin B12 < 300 
with Methylmalonic acid > 318 
(B12/MA Criteria) 
OR: 
2) Methylmalonic acid >318 (MA Only Criterion) 
All analyses were conducted separately for each crite-
rion for B12 deficiency. All tests were performed at α = 
0.05. 
Differences in the distributions between metformin 
users (n = 47) and non-metformin users (n = 41) in B12 
deficiency for categorical variables were assessed using 
Fisher’s exact test. Fisher’s exact test was also used to 
evaluate relationships between dose (for metformin users 
only) and demographic characteristics (Age, Sex, Race) 
and the prevalence of B12 deficiency. Dose was di-
chotomized as “≤1000 mg” and “>1000 mg”. The Man-
tel-Haenszel test was used to investigate the relationships 
of sex and age to Vitamin B12 deficiency, while control-
ling for metformin use. 
Differences between Vitamin B12 deficient subjects 
and non-deficient subjects by Homocysteine, CBC, He-
moglobin A1C, and Creatinine levels were measured 
using the Wilcoxon rank sum test. Logistic regression 
analysis was used to assess the potential confounding 
effects of diabetes and A1C blood levels. Multiple logis-
tic regression models were used to evaluate the relation-
ship between Vitamin B12 deficiency (B12/MA Criteria) 
and metformin use and Vitamin B12 deficiency (using 
both criteria) with the prevalence of anemic subjects.  
4. RESULTS 
4.1. Analysis for B12/MA Criteria  
There were 41 control subjects and 47 case subjects. 
The prevalence of B12 deficiency did not differ sig-
nificantly between groups (taking metformin vs. not tak-
ing). The prevalence rates were 17.1% and 12.8%, re-
spectively (Table 1) 
Among the 47 metformin users, the daily dosage was 
1000 mg or less in 27 subjects and more than 1000 mg in 
20 subjects. For these subjects the rates of deficiency 
were 14.8% and 10.0%, respectively, which was not sig-
nificantly different (Table 2). 
There was a significant association between age and 
B12 Deficiency (p < 0.031) (Table 3). The prevalence of  
 
Table 1. Prevalence of B12 deficiency based on both criteria. 
 Vit B12 Deficient Not Vit B12 Deficient P 
Criterion 1 17.07 12.77 0.76 
Criterion 2 31.71 19.15 0.22 
 
Table 2. B12 deficiency in relation to metformin dosing. 
 ≤1000 mg >1000 mg P 
Criterion 1 14.81 10 1 
Criterion 2 14.81 25 0.47 
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Table 3. Various factors and their association with B12 defi-
ciency, evaluated seperately for each Criterion. 
  Criterion 1 Criterion 2 
Male 16.67 P = 0.76 22.92 P = 0.63
Sex 
Female 12.5  27.5  
<51 9.09 P = 0.03 22.73 P = 0.79
51 ≤ 62 4.55  18.18  
62 ≤ 75 34.78  30.43  
Age 
75+ 9.52  28.57  
Non White 6.67 P = 0.45 13.33 P = 0.34
Race 
White 16.44  27.4  
 
B12 deficiency was low and relatively constant in the 
younger three age groups; in the 62 ≤ 75 age group, the 
prevalence is significantly higher. 
No other variables were significantly associated with 
metformin use. In particular, Table 4 shows means for 
laboratory parameters according to deficiency status, 
regardless of metformin usage. None of these parameters 
differed significantly between deficient and non-deficient 
subjects. 
All logistic regression models failed to demonstrate 
metformin use or B12 deficiency as significant predictors 
of anemia. (p = 0.93 and p = 0.17 respectively).  
4.2. Analysis for MA-Only Criterion  
(Criterion 2) 
There were 41 non-metformin subjects and 47 met-
formin subjects. 
For the primary question, the prevalence of B12 defi-
ciency did not differ significantly between groups (met-
formin no vs. yes). The prevalence rates were 31.7% and 
9.2%, respectively (Table 1). 
Among the 47 metformin users, the daily dosage was 
1000 mg or less for 27 subjects and more than 1000 mg 
for 20 subjects.  For these subjects the rates of defi-
ciency were 14.8% and 25.0%, respectively, which were 
not significantly different (Table 2). 
Unlike for the B12/MA criteria (criteria 1), there was 
no association between age and deficiency rates (Table 
3). 
Hemoglobin, along with homocysteine counts, was 
significantly different between vitamin B12 deficient and 
non-deficient subjects via criterion 2 only. For Hemoglo-
bin, the p value was <0.042, and for homocysteine, p < 
0.0003. 
5. DISCUSSION 
Previous studies have indicated that there is a correla-
tion between the use of metformin, vitamin B12 defi-
ciency, and elevated homocysteine levels. However, the 
role of MMA has not been well studied. In this study, 
where elevated MMA levels were used to categorize vi-
tamin B12 deficiency, a correlation between metformin 
use and B12 deficiency was not observed. Of note, two 
patients in each group had normal MMA levels in the 
presence of abnormally low serum vitamin B12 levels 
(<180 pg/ml). Of 22 patients with low normal vitamin 
B12 concentrations (180 - 300 pg/ml), only 6 had ele-
vated MMA levels. Alternatively, of 22 patients with 
elevated MMA levels, only 9 had vitamin B12 concen-
trations <300 pg/ml. If MMA is considered a more sensi-
tive test for clinically relevant vitamin B12 deficiency 
[6], then the prevalence of such deficiency may have 
been underestimated in previous studies. When we ana-
lyzed our data we used a subset of patients who have  
 
Table 4. Lab parameter means and their significance between deficient and non deficient for both methods. 
Deficient Not Deficient Method 1 Deficient Not Deficient Method 2
Lab Parameter 
Method 1 Mean Method 1 Mean P value Method 2 Mean Method 2 Mean P value 
Homocysteine 14.95 11.81 0.07 16.67 10.81 0.0003 
HgA1C 7.18 7.37 1 7.28 7.36 0.83 
Createnine 1.15 1.17 0.56 1.51 1.05 0.07 
White Blood Cell Count 10.58 8.92 0.08 9.42 9.08 0.67 
Hemoglobin 12.63 12.47 0.86 11.92 12.68 0.04 
Hematocrit 37.42 36.78 0.92 35.35 37.39 0.55 
Mean Corpuscular Volume 86.84 86.25 0.88 85.12 86.74 0.36 
Mean Corpuscular Hemoglobin 29.35 29.28 0.58 28.77 29.47 0.38 
Platalets 228.92 234.55 0.6 234.41 233.48 0.94 
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high MMA levels (>318 nmol/L) regardless of B12 lev- 
els and found no difference in vitamin B12 deficiency. 
Likewise, an overestimation of true B12 deficiency may 
occur when measured with B12 levels, as MMA is 
highly specific for ruling out disease. The serum vitamin 
B12 concentration is known to fluctuate more readily 
than MMA after alterations in eating habits and transfu-
sions along with other factors; further, serum vitamin 
B12 levels may not reflect intracellular B12 concentra-
tions [7]. 
Greater homocysteine concentrations were observed in 
the patients not on metformin therapy, in contrast to a 
prior study (4). However, this large, randomized-con- 
trolled trial included patients treated with metformin 
while they were on insulin treatment; the significance of 
which is unknown. Other smaller studies have demon-
strated little or no effect of metformin treatment on ho-
mocysteine levels [5,8-11]. In the current study, possible 
confounding factors including familial hyperhomocys-
teinemia, inflammation, dietary factors other than vege-
tarianism; as well, documented folate deficiency may 
have affected homocysteine levels.  
Additional limitations of this study include a small 
sample size, lack of information of other confounding 
variables such as duration of therapy and dosage, and 
absence of signs and symptoms of vitamin B12 defi-
ciency. 
In concordance with current guidelines, MMA levels 
should be used in combination with vitamin B12 levels 
to determine vitamin B12 status. Thus, additional studies 
examining B12 status in diabetes patients should utilize 
MMA measurements. Larger, randomized-controlled trials 
utilizing MMA are needed to better assess the risk of 
metformin therapy and development of clinically rele-
vant vitamin B12 deficiency. 
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